This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile of Aleglitazar, compared with placebo in patients with type 2 diabetes experiencing an acute coronary syndrome. A total of 7226 patients were randomized at 12 weeks post-acute coronary event to receive Aleglitazar 150 ug or placebo. The study...

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients with undetectable ultrasensitive troponin ( Conclusion The undetectable ultrasensitive troponin T values in patients with chest pain and no signs of ischemia on the electrocardiogram has an accuracy close to 100%...

Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing cardiovascular events in patients with chronic ischemic heart disease.Lp-PLA2 is an enzyme found in the blood andatherosclerotic plaques and high levels are associated with an increased risk of cardiovascular events.Direct inhibition of this enzyme with proinflammatory Daraplabid may...

There is evidence that inflammation would have an impact on the prognosis of patients experiencing acute coronary syndromes. The phospholipase A2 inhibitor Varespladib has positive effects on lipid and inflammatory markers. This double-blind, multicenter planned to randomize 5145 patients with acute coronary syndrome to Varespladib or placebo. The primary endpoint was a combination of cardiovascular...

The STREAM study (Strategic Reperfusion Early After Myocardial Infarction) that included 1891 patients gave support to the fibrinolytic infusion strategy in the ambulance in patients treated within 3 hours of stroke and who cannot receive primary angioplasty within the hour versus primary angioplasty. The primary end point was a composite of death from any cause,...

The phenomenon of reperfusion injury is responsible for 50 % of the final infarct size. Several pharmacological and non-pharmacological agents administered before or during the ischemic period could significantly reduce infarct size in experimental studies in humans, but the results were inconsistent. This study tested the hypothesis that intravenous nitroprusside infusion immediately before the opening...

SORT OUT V randomized trial (Odense University Hospital, Denmark) compared Nobori stent, a drug-eluting stent with biodegradable polymer eluting biolimus, versus CYPHER a drug-eluting stent with permanent polymer in the real world. Danish researchers used a non-inferiority design, by means of a primary objective of the study, the combined rate of major cardiac events (cardiac...

CLI-randomized study CLI-OPCI (n = 670, 1:1) evaluated the impact of stent implantation guided by angiography and optical coherence tomography (OCT), versus angioplasty guided alone by angiography. All patients who had been subjected to stent placement were then evaluated by angiography.  Arm OCT, after an optimal angiographic result, an intracoronary OCT evaluation was performed. In...

 IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.  Holger Thiele2012-08-26 Original title: IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock

Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted a reduction in the age of presentation, especially in women under 60 years with increased incidence of smoking and obesity. Pain-center time was significantly reduced, while increasing the number of patients...